The APOE gene on chromosome 19, responsible for coding apolipo-protein E, is genetically linked to both common late-onset familial and sporadic forms of AD. The human APOE gene comprises three alleles: -ε2, -ε3, and -ε4 distributed in the population at 7%, 79%, and 14%, respectively.

Having one or two copies of the ε4 allele in APOE gene is statistically associated with an increased risk of developing AD. Approximately 65% of AD patients in the Caucasian population carry the APOE ε4 allele.

Backed by clinical science, the CE-IVDR APO-Easy® Genotyping Kit is a result of an extensive research and an innovative and highly-sensitive product clinicially validated by multicentric clinical studies in 7 countries on ~960 patients with neurodegenerative diseases including patients with Mild Cognitive Impairment (MCI), mild and moderate to severe AD, Frontotemporal Dementia (FTD), Lewy Body Dementia (LBD), Parkinson Disease Dementia (PDD), Cortico-Basal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP).

The APO-Easy® Genotyping kit is a CE-IVDR qualitative in vitro diagnostic (IVD) test based on RT-PCR, intended for the detection of two single-nucleotide-polymorphisms (SNP) rs429358 and rs7412 in human genomic DNA from whole blood, saliva and buccal swab through the use of fluorescently labeled probes (FAM and VIC) allowing allelic discrimination and determination of six Apolipoprotein E (APOE) genotypes: e2/e2, e2/e3, e3/e3, e2/e4, e3/e4, and e4/e4.

• 100% specific, reliable and accurate
• No false positive or false negative results
• Determination of -ε2, -ε3, and -ε4 alleles